{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:01:28Z","timestamp":1793833288377,"version":"4.6.1"},"reference-count":57,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is caused by an unstable cytosine adenine guanine (CAG) trinucleotide repeat expansion encoding a polyglutamine tract in the huntingtin protein. Previously, we identified several up- and down-regulated protein molecules in the striatum of the Hdh(CAG)150 knock-in mice at 16 months of age, a mouse model which is modeling the early human HD stage. Among those molecules, aconitase 2 (Aco2) located in the mitochondrial matrix is involved in the energy generation and susceptible to increased oxidative stress that would lead to inactivation of Aco2 activity. In this study, we demonstrate decreased Aco2 protein level and activity in the brain of both Hdh(CAG)150 and R6\/2 mice. Aco2 activity was decreased in striatum of Hdh(CAG)150 mice at 16 months of age as well as R6\/2 mice at 7 to 13 weeks of age. Aco2 activity in the striatum of R6\/2 mice could be restored by the anti-oxidant, N-acetyl-l-cysteine, supporting that decreased Aco2 activity in HD is probably caused by increased oxidative damage. Decreased Aco2 activity was further found in the peripheral blood mononuclear cells (PBMC) of both HD patients and pre-symptomatic HD mutation (PreHD) carriers, while the decreased Aco2 protein level of PBMC was only present in HD patients. Aco2 activity correlated significantly with motor score, independence scale, and functional capacity of the Unified Huntington\u2019s Disease Rating Scale as well as disease duration. Our study provides a potential biomarker to assess the disease status of HD patients and PreHD carriers.<\/jats:p>","DOI":"10.3390\/ijms18112480","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T11:23:20Z","timestamp":1511263400000},"page":"2480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Altered Aconitase 2 Activity in Huntington\u2019s Disease Peripheral Blood Cells and Mouse Model Striatum"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-0353","authenticated-orcid":false,"given":"Chiung-Mei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou; Chang-Gung University College of Medicine, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ru","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou; Chang-Gung University College of Medicine, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou; Chang-Gung University College of Medicine, Taoyuan 33305, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"HDCRG (The Huntington\u2019s Disease Collaborative Research Group) (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell, 72, 971\u2013983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrg1690","article-title":"Therapeutics development for triplet repeat expansion diseases","volume":"6","author":"Fischbeck","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/1073858405280639","article-title":"The ubiquitin-proteasome system in Huntington\u2019s disease","volume":"11","author":"Valera","year":"2005","journal-title":"Neuroscientist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","article-title":"Transcriptional signatures in Huntington\u2019s disease","volume":"83","author":"Cha","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1196\/annals.1427.008","article-title":"Evidence of oxidant damage in Huntington\u2019s disease: Translational strategies using antioxidants","volume":"1147","author":"Stack","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1196\/annals.1427.018","article-title":"Mitochondria and Huntington\u2019s disease pathogenesis: Insight from genetic and chemical models","volume":"1147","author":"Browne","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/gb-2005-6-3-210","article-title":"Connecting the dots in Huntington\u2019s disease with protein interaction networks","volume":"6","author":"Giorgini","year":"2005","journal-title":"Genome Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Wild","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: A clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12035-009-8097-5","article-title":"Targeting Glial Cells to Elucidate the Pathogenesis of Huntington\u2019s Disease","volume":"14","author":"Hsiao","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington\u2019s disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-6147(00)01884-8","article-title":"Mouse models of Huntington\u2019s disease","volume":"23","author":"Menalled","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1523\/JNEUROSCI.1830-07.2007","article-title":"Longitudinal evaluation of the Hdh (CAG)150 knock-in murine model of Huntington\u2019s disease","volume":"27","author":"Heng","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K","article-title":"Mitochondrial dysfunction and free radical damage in the Huntington R6\/2 transgenic mouse","volume":"47","author":"Tabrizi","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","article-title":"Biochemical abnormalities and excitotoxicity in Huntington\u2019s disease brain","volume":"45","author":"Tabrizi","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.freeradbiomed.2008.05.014","article-title":"Proteomic and oxidative stress analysis in human brain samples of Huntington disease","volume":"45","author":"Sorolla","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1074\/mcp.M600356-MCP200","article-title":"Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach","volume":"6","author":"Chiang","year":"2007","journal-title":"Mol. Cell. Proteom."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Huntington Study Group (1996). Unified Huntington\u2019s Disease Rating Scale: Reliability and Consistency. Mov. Disord., 11, 136\u2013142.","DOI":"10.1002\/mds.870110204"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","article-title":"The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies","volume":"2","author":"Li","year":"2005","journal-title":"NeuroRx"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2001.00689.x","article-title":"Increased oxidative damage to DNA in a transgenic mouse model of Huntington\u2019s disease","volume":"79","author":"Bogdanov","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1460-9568.2005.03985.x","article-title":"Akt is altered in an animal model of Huntington\u2019s disease and in patients","volume":"21","author":"Colin","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbadis.2010.05.001","article-title":"Reduced creatine kinase as a central and peripheral biomarker in Huntington\u2019s disease","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1074\/mcp.M800277-MCP200","article-title":"A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for Huntington\u2019s disease","volume":"8","author":"Zabel","year":"2009","journal-title":"Mol. Cell. Proteom."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/hmg\/ddm057","article-title":"Hsp27 overexpression in the R6\/2 mouse model of Huntington\u2019s disease: Chronic neurodegeneration does not induce Hsp27 activation","volume":"16","author":"Zourlidou","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bj3600209","article-title":"Selectivity of protein oxidative damage during aging in Drosophila melanogaster","volume":"360","author":"Das","year":"2001","journal-title":"Biochem. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: Selective vulnerability of the basal ganglia","volume":"41","author":"Browne","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington\u2019s disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/11.9.1137","article-title":"Hock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin","volume":"11","author":"Wyttenbach","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","article-title":"Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients","volume":"359","author":"Chen","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1074\/mcp.M500090-MCP200","article-title":"Proteomic analysis of protein expression and oxidative modification in R6\/2 transgenic mice: A model of Huntington disease","volume":"4","author":"Perluigi","year":"2005","journal-title":"Mol. Cell. Proteom."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.96.13.7388","article-title":"Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington\u2019s disease","volume":"96","author":"Karpuj","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1046\/j.1471-4159.1999.02018.x","article-title":"Tissue transglutaminase is increased in Huntington\u2019s disease brain","volume":"73","author":"Lesort","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s11064-005-8796-x","article-title":"Mitochondrial aconitase is a transglutaminase 2 substrate: Transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain","volume":"30","author":"Kim","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.4049\/jimmunol.180.11.7697","article-title":"Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation","volume":"180","author":"Maiuri","year":"2008","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Naseri, N.N., Bonica, J., Xu, H., Park, L.C., Arjomand, J., Chen, Z., and Gibson, G.E. (2016). Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington\u2019s Disease Patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160384"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1038\/tp.2014.131","article-title":"N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6\/1 mouse model of Huntington\u2019s disease","volume":"5","author":"Wright","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","article-title":"Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington\u2019s disease","volume":"86","author":"Klivenyi","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2010.03.017","article-title":"Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington\u2019s disease","volume":"49","author":"Stack","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/13518","article-title":"Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1096\/fj.03-0079fje","article-title":"Aberrant A2A receptor function in peripheral blood cells in Huntington\u2019s disease","volume":"17","author":"Varani","year":"2003","journal-title":"FASEB. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ajmg.b.30223","article-title":"Adenosine A(2A) receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington\u2019s disease","volume":"139","author":"Maglione","year":"2005","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/brain\/awl027","article-title":"Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles","volume":"129","author":"Underwood","year":"2006","journal-title":"Brain"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","article-title":"Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington\u2019s disease mutation in peripheral lymphocytes","volume":"27","author":"Battista","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mochel, F., Charles, P., Seguin, F., Barritault, J., Coussieu, C., Perin, L., Le Bouc, Y., Gervais, C., Carcelain, G., and Vassault, A. (2007). Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000647"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chang, K.H., Chen, Y.C., Wu, Y.R., Lee, W.F., and Chen, C.M. (2012). Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington\u2019s disease patients. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046492"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma Inflammatory biomarkers for Huntington\u2019s disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","article-title":"Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease","volume":"31","author":"Cheng","year":"2016","journal-title":"J. Nutr. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1073\/pnas.1104409108","article-title":"Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/11\/2480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:50:37Z","timestamp":1760208637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/11\/2480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["ijms18112480"],"URL":"https:\/\/doi.org\/10.3390\/ijms18112480","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}